Navarini, Alexander A; French, Lars E (2018). Survival of Second-Line Biologics in Psoriasis: The British BADBIR Registry Data Informs Daily Practice. Journal of Investigative Dermatology, 138(4):726-728.
Psoriasis is one of the most chronic diseases in dermatology. Only a small percentage of patients ever experience relapse-free survival. The constant presence of plaques and comorbidities that affect the cardiovascular system, joints, and other organs greatly impair patients' quality of life. In addition, the life expectancy of psoriatic patients is shortened by several years. Hence, long-term and ideally systemic treatment with minimal adverse effects may be warranted.
Psoriasis is one of the most chronic diseases in dermatology. Only a small percentage of patients ever experience relapse-free survival. The constant presence of plaques and comorbidities that affect the cardiovascular system, joints, and other organs greatly impair patients' quality of life. In addition, the life expectancy of psoriatic patients is shortened by several years. Hence, long-term and ideally systemic treatment with minimal adverse effects may be warranted.
| Item Type: | Journal Article, refereed, further contribution |
|---|---|
| Communities & Collections: | 04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic |
| Dewey Decimal Classification: | 610 Medicine & health |
| Scopus Subject Areas: | Life Sciences > Biochemistry
Life Sciences > Molecular Biology Health Sciences > Dermatology Life Sciences > Cell Biology |
| Uncontrolled Keywords: | Cell Biology, Biochemistry, Molecular Biology, Dermatology |
| Language: | English |
| Date: | April 2018 |
| Deposited On: | 19 Apr 2018 06:36 |
| Last Modified: | 26 Nov 2023 08:12 |
| Publisher: | Elsevier |
| ISSN: | 0022-202X |
| OA Status: | Closed |
| Free access at: | Publisher DOI. An embargo period may apply. |
| Publisher DOI: | https://doi.org/10.1016/j.jid.2018.02.008 |
| PubMed ID: | 29579453 |
Navarini, Alexander A